You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Fig. 1

Progression free survival. a Progression free survival. b Progression free survival by PS. c Progression free survival by MMR status. d Progression free survival by PD-L1 positivity in tumor cell. MMR, mismatch repair; MMR-D, mismatch repair deficient; MMR-P, mismatch repair proficient; PD-L1, programmed cell death-1 ligand-1; PS, Eastern Cooperative Oncology Group performance status; Pts, patient

Back to article page